We are live on
!
Find out more
PCA
Pallas Capital Advisors Portfolio holdings
AUM
$3.25B
1-Year Est. Return
40.07%
This Fund
S&P 500
This Quarter
Est. Return
+9.01%
1 Year Est. Return
+40.07%
3 Year Est. Return
+71.82%
5 Year Est. Return
+73.39%
10 Year Est. Return
–
AUM
$2.63B
AUM Growth
+$217M
(+9%)
Cap. Flow
+$58.3M
Cap. Flow
% of AUM
2.22%
Top 10 Holdings %
Top 10 Hldgs %
32.98%
Holding
947
New
185
Increased
338
Reduced
311
Closed
89
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Schwab Fundamental International Large Company Index ETF
FNDF
|
+$21.7M |
| 2 |
Dimensional International Value ETF
DFIV
|
+$16.9M |
| 3 |
Fidelity Enhanced International ETF
FENI
|
+$10.1M |
| 4 |
Janus Henderson Mortgage-Backed Securities ETF
JMBS
|
+$8.73M |
| 5 |
NVIDIA
NVDA
|
+$7.97M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Goldman Sachs ActiveBeta International Equity ETF
GSIE
|
+$19M |
| 2 |
iShares MSCI Intl Quality Factor ETF
IQLT
|
+$18.6M |
| 3 |
Schwab International Equity ETF
SCHF
|
+$9.89M |
| 4 |
Synopsys
SNPS
|
+$7.4M |
| 5 |
Qualcomm
QCOM
|
+$6.74M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.15% |
| 2 | Technology | 14.41% |
| 3 | Financials | 7.34% |
| 4 | Consumer Discretionary | 5.99% |
| 5 | Industrials | 5.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
826
Coty
COTY
$2.48B
| $52.1K | ﹤0.01% |
11,199
-28,974
| -72% | -$143K |
|
827
Xeris Biopharma Holdings
XERS
$1.45B
| $51.4K | ﹤0.01% |
11,005
-4,338
| -28% | -$19.9K |
|
828
Cytek Biosciences
CTKB
$546M
| $47.8K | ﹤0.01% |
+14,069
| New | +$46.9K |
|
829
Transocean
RIG
$5.82B
| $45.6K | ﹤0.01% |
17,600
+478
| +3% | +$1.23K |
|
830
Critical Metals Corp
CRML
$1.06B
| $44.7K | ﹤0.01% |
+12,481
| New | +$22.8K |
|
|
LPRO
831
DELISTED
Open Lending Corp
LPRO
| $44.4K | ﹤0.01% |
+22,891
| New | +$37K |
|
832
Conduent
CNDT
$264M
| $43.4K | ﹤0.01% |
+16,432
| New | +$38.6K |
|
833
Ardagh Metal Packaging
AMBP
$3.01B
| $43.4K | ﹤0.01% |
+10,132
| New | +$36.7K |
|
834
Humacyte
HUMA
$194M
| $41.5K | ﹤0.01% |
+19,877
| New | +$38.2K |
|
835
Taboola.com
TBLA
$1.11B
| $40.7K | ﹤0.01% |
+11,130
| New | +$36.3K |
|
|
VTYX
836
DELISTED
Ventyx Biosciences
VTYX
| $38.1K | ﹤0.01% |
+17,824
| New | +$28.8K |
|
837
Sera Prognostics
SERA
$81.1M
| $38K | ﹤0.01% |
13,711
-146
| -1% | -$361 |
|
838
Lexicon Pharmaceuticals
LXRX
$1.1B
| $34.8K | ﹤0.01% |
36,765
+557
| +2% | +$361 |
|
839
SmartRent
SMRT
$272M
| $30.5K | ﹤0.01% |
30,788
+17,312
| +128% | +$15.5K |
|
|
MRSN
840
DELISTED
Mersana Therapeutics
MRSN
| $28.6K | ﹤0.01% |
3,868
+87
| +2% | +$764 |
|
841
Leslie's
LESL
$11M
| $26.8K | ﹤0.01% |
3,194
+2,005
| +169% | +$26.4K |
|
842
SES AI
SES
$208M
| $23.8K | ﹤0.01% |
26,773
-242
| -0.9% | -$203 |
|
843
Nkarta
NKTX
$172M
| $21.3K | ﹤0.01% |
12,836
-305
| -2% | -$559 |
|
844
Tilray
TLRY
$622M
| $21K | ﹤0.01% |
5,072
-1,695
| -25% | -$7.69K |
|
845
ChargePoint
CHPT
$161M
| $18.6K | ﹤0.01% |
1,323
-4,624
| -78% | -$62K |
|
846
Fate Therapeutics
FATE
$326M
| $17.2K | ﹤0.01% |
15,336
+1,104
| +8% | +$1.28K |
|
847
GoPro
GPRO
$126M
| $16.9K | ﹤0.01% |
22,293
-4,645
| -17% | -$3.02K |
|
848
Tenaya Therapeutics
TNYA
$163M
| $16.4K | ﹤0.01% |
26,832
-168
| -0.6% | -$86 |
|
849
Hain Celestial
HAIN
$53.7M
| $15.8K | ﹤0.01% |
+10,403
| New | +$24.3K |
|
850
Erasca
ERAS
$6.39B
| $15.7K | ﹤0.01% |
12,325
+815
| +7% | +$1.09K |
|
Similar funds
AIP
BCI
EWA
SYBT
PCM
KIM
YCM
SC
Pallas Capital Advisors's Q2 2025 Portfolio in Review
As of Q2 2025, Pallas Capital Advisors held 947 positions worth $2.63B, up 9% from $2.41B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Pallas Capital Advisors's Q2 2025 filing shows 185 new, 338 increased, 311 reduced and 89 closed positions. Its largest new stake was Capital Group Dividend Value ETF: 163,663 shares worth $6.46M. The largest sale was Goldman Sachs ActiveBeta International Equity ETF, an estimated $19M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 23% a quarter earlier, followed by Technology and Financials.
- Pallas Capital Advisors's largest Q2 2025 buy was Capital Group Dividend Value ETF: 163,663 shares worth $6.46M.
- Pallas Capital Advisors added most to Schwab Fundamental International Large Company Index ETF in Q2 2025, an estimated $21.7M increase.
- Pallas Capital Advisors's biggest Q2 2025 reduction was Goldman Sachs ActiveBeta International Equity ETF, cutting an estimated $19M.
- Pallas Capital Advisors fully exited Synopsys in Q2 2025, selling an estimated $7.4M.
- Pallas Capital Advisors's ten largest holdings make up 33% of its $2.63B portfolio in Q2 2025.
- Pallas Capital Advisors opened 185 new positions and closed 89 in Q2 2025.
- Pallas Capital Advisors's portfolio value rose 9% quarter-over-quarter to $2.63B.
Based on Pallas Capital Advisors's 13F filing for Q2 2025, filed 9 Jul 2025.